News for Dynavax Technologies Corporation (0IDA.L)

Dynavax Technologies Corporation (NASDAQ:DVAX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On June 23, Citizens JMP analyst Roy Buchanan reiterated a Buy rating on Dynavax Technologies Corporation (NASDAQ:DVAX) and set a price target of $31.00. The company reported record net product revenue for HEPLISAV-B in fiscal Q1 […]

Deep Track Capital, LP, (together with its affiliates, ”œDeep Track” or ”œwe”), one of the largest shareholders of Dynavax Technologies Corporation (NASD

Dynavax Technologies Corporation has encouraged its shareholders to cast their votes in favor of re-electing its four current directors. The directors up for re

PR NewswireEMERYVILLE, Calif., June 9, 2025 Dynavax's Strategy is Delivering Significant Long-Term Stockholder ValueDynavax's Nominees Are Vastly Superior

Deep Track Capital, LP, (together with its affiliates, ”œDeep Track” or ”œwe”), one of the largest shareholders of Dynavax Technologies Corporation (NASD

Deep Track Capital, LP, (together with its affiliates, ”œDeep Track” or ”œwe”), one of the largest shareholders of Dynavax Technologies Corporation (NASD

Deep Track Capital criticizes Institutional Shareholder Services (ISS) for inadequate analysis of Dynavax Technologies (DVAX) board performance. The inv

PR NewswireEMERYVILLE, Calif., May 23, 2025 ISS Recognizes There is No Case for ChangeDynavax's Superior Strategy and Current Board are Best Equipped to De

Deep Track Capital, LP, (together with its affiliates, ”œDeep Track” or ”œwe”), one of the largest shareholders of Dynavax Technologies Corporation (NASD

PR NewswireEMERYVILLE, Calif., May 12, 2025 Presentation Underscores Deep Track's Value Destructive Plan and Inferior Slate of Director Nominees Urges Stoc

PR NewswireEMERYVILLE, Calif., May 7, 2025 In the news release, Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Resu

Dynavax Technologies (DVAX) revises stockholder value metrics to over $900 million and 62% return. Q1 2025 revenue jumps 34% YoY to $68.2 million, drive

Dynavax Technologies Corporation (NASDAQ:DVAX) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ETCompany ParticipantsPaul Cox - Vice President,...

PR NewswireEMERYVILLE, Calif., May 6, 2025 Record HEPLISAV-B® first quarter net product revenue of $65 million, representing 36% year-over-year growthTop-

Deep Track Capital, LP, (together with its affiliates, ”œDeep Track” or ”œwe”) one of the largest shareholders of Dynavax Technologies Corporation (NASDA

PR NewswireEMERYVILLE, Calif., April 29, 2025 Mails Letter to Stockholders Urging Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD

Dynavax Technologies (DVAX) sees a strong performance with its HEPLISAV-B® vaccine, projecting $305-$325 million in revenue for 2025 after achieving $268

PR NewswireEMERYVILLE, Calif., April 22, 2025 EMERYVILLE, Calif., April 22, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a commerc

PR NewswireEMERYVILLE, Calif., April 17, 2025 Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy CardHighlights Record F